Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00735514 · ClinicalTrials.gov registry record
Compliance to Vaginal Dilation Therapy in Patients Who Have Undergone Radiation Therapy For Stage IB, Stage IIA, Stage IIB, Stage IIIA, or Stage IIIB Cervical Cancer or Stage IA, Stage IB, Stage IIA, or Stage IIB Endometrial Cancer
A clinical trial, sponsored by Case Comprehensive Cancer Center.
- Completed
- Registry status
- 83
- Enrollment target
NCT00735514: Completed study, sponsored by Case Comprehensive Cancer Center.
NCT00735514 is a clinical trial that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 83 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00735514 has completed, sponsored by Case Comprehensive Cancer Center.
- COMPLETED
- Registry status
- 83 participants
- Enrollment target
Study Summary
RATIONALE: Understanding how well patients comply with their treatment regimen may help doctors determine best treatment and ongoing care for future patients. PURPOSE: This phase I study is looking at compliance with vaginal dilation therapy in women who have undergone radiation therapy for stage IB, stage IIA, stage IIB, stage IIIA, or stage IIIB cervical cancer or stage IA, stage IB, stage IIA, or stage IIB endometrial cancer.
Interventions
- OTHER questionnaire administration
- PROCEDURE psychosocial assessment and care
- PROCEDURE management of therapy complications
- PROCEDURE assessment of therapy complications
- BEHAVIORAL compliance monitoring
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2008-07 |
| Est. Completion | 2010-05 |
What the finished NCT00735514 record still lists
NCT00735514 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 83 participants, a relatively small participant target.
The record links to 0 conditions, and to 5 interventions - of which questionnaire administration is the first listed.
NCT00735514 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00735514 about?
NCT00735514 is a clinical study titled "Compliance to Vaginal Dilation Therapy in Patients Who Have Undergone Radiation Therapy For Stage IB, Stage IIA, Stage IIB, Stage IIIA, or Stage IIIB Cervical Cancer or Stage IA, Stage IB, Stage IIA, or Stage IIB Endometrial Cancer". RATIONALE: Understanding how well patients comply with their treatment regimen may help doctors determine best treatment and ongoing care for future patients. PURPOSE: This phase I study is looking at compliance with vaginal dilation therapy in women who have undergone radiation therapy for stage I...
What is the current status of trial NCT00735514?
This trial is currently completed. The enrollment target is 83 participants. The study started on 2008-07. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00735514?
The interventions under investigation include: questionnaire administration (OTHER), psychosocial assessment and care (PROCEDURE), management of therapy complications (PROCEDURE), assessment of therapy complications (PROCEDURE), compliance monitoring (BEHAVIORAL).
Who is sponsoring clinical trial NCT00735514?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02974647 · 83 participants · Phase 2
Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
- NCT03919292 · 83 participants · Phase 1
Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca
- NCT04626674 · 83 participants · Phase 1
A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)
- NCT05277168 · 83 participants · Phase 1
A Trial TO Evaluate THE Safety, Tolerability, Pharmacokinetics, AND Efficacy OF Shr-a1904 IN Subjects With Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia